| Literature DB >> 24842338 |
Mahmoud H Mosli1, William J Sandborn2, Richard B Kim3, Reena Khanna4, Bandar Al-Judaibi5, Brian G Feagan4.
Abstract
The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease. Defined targets that guide intensification of therapy are critical interventions. In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies. This review discusses the current application of personalized medicine to the management of IBD.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24842338 DOI: 10.1038/ajg.2014.110
Source DB: PubMed Journal: Am J Gastroenterol ISSN: 0002-9270 Impact factor: 10.864